Firefly Aerospace Subsidiary SciTec Receives Agreement to Advance Space Force’s Space-Based Missile Defense Under Golden Dome

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alico to Present at the LD Micro Invitational XVI

Axe Compute Inc. (NASDAQ: AGPU) CEO Chris Miglino to Appear on Schwab Network May 4 and Cheddar May 6

NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress

RESEARCH FRONTIERS TO HOST FIRST QUARTER 2026 CONFERENCE CALL

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Reliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA’s Biotech Division

Whirlpool Foundation Announces 2026 Sons & Daughters Scholarship Recipients

CACI Appoints Christopher Monoski as Executive Vice President, Manufacturing

EVERYWHERE Communications Partners with Parsons to Enable Resilient, Beyond-Line-of-Sight Autonomous Drone Operations Under SBIR Initiative

L’Oréal and Adeia Enter Multi-Year License Agreement

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Safe Pro Launches New Growth Team Led by Brian Mack as Chief Growth Officer and Benjamin Chitty as VP of Government Growth

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis